Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy

Thompson, 2010, Antifibrotic therapies: will we ever get there?, Curr. Gastroenterol. Rep., 12, 23, 10.1007/s11894-009-0080-9 Popper, 1970, Hepatic fibrosis. Correlation of biochemical and morphologic investigations, Am. J. Med., 49, 707, 10.1016/S0002-9343(70)80135-8 Pellicoro, 2012, Reversibility of liver fibrosis, Fibrogenesis Tissue Repair, 5, S26, 10.1186/1755-1536-5-S1-S26 Poynard, 2010, Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest), BMC Gastroenterol., 10, 40, 10.1186/1471-230X-10-40 Ronot, 2010, Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT, Radiology, 256, 135, 10.1148/radiol.10091295 Khan, 2000, Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients, Alcohol Alcohol., 35, 286, 10.1093/alcalc/35.3.286 Soriano, 2012, Treatment failure with new hepatitis C drugs, Expert Opin. Pharmacother., 13, 313, 10.1517/14656566.2012.653341 Poveda, 2014, Update on hepatitis C virus resistance to direct-acting antiviral agents, Antiviral Res., 108, 181, 10.1016/j.antiviral.2014.05.015 Jo, 2015, Retreatment with peginterferon and ribavirin in chronic hepatitis C, World J. Gastroenterol., 21, 1994, 10.3748/wjg.v21.i6.1994 Papastergiou, 2015, Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6, World J. Clin. Cases, 3, 210, 10.12998/wjcc.v3.i3.210 Simula, 2010, Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics, Proteomics Clin. Appl., 4, 782, 10.1002/prca.201000049 Fujita, 2007, Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C, J. Gastroenterol. Hepatol., 22, 1886, 10.1111/j.1440-1746.2006.04759.x Miura, 2008, Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity, Hepatology, 48, 1420, 10.1002/hep.22486 Nishina, 2008, Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription, Gastroenterology, 134, 226, 10.1053/j.gastro.2007.10.011 Jaroszewicz, 2010, Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C, World J. Gastroenterol., 16, 1747, 10.3748/wjg.v16.i14.1747 Strnad, 2014, Hepcidin as a predictor of treatment response in chronic hepatitis C infection, Hepatology, 59, 1648, 10.1002/hep.26656 Liu, 2012, Inhibition of translation initiation factors might be the potential therapeutic targets for HCV patients with hepatic iron overload, Med. Hypotheses, 78, 142, 10.1016/j.mehy.2011.10.011 Brittenham, 2003, Iron chelators and iron toxicity, Alcohol, 30, 151, 10.1016/S0741-8329(03)00101-0 Hatcher, 2009, Synthetic and natural iron chelators: therapeutic potential and clinical use, Future Med. Chem., 1, 1643, 10.4155/fmc.09.121 Sakaida, 1995, Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine, Scand. J. Gastroenterol., 30, 61, 10.3109/00365529509093237 Schnellmann, 1999, Deferoxamine delays the development of the hepatotoxicity of acetaminophen in mice, Toxicol. Lett., 106, 79, 10.1016/S0378-4274(99)00021-1 Ritter, 2004, Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats, Crit. Care Med., 32, 2079, 10.1097/01.CCM.0000142699.54266.D9 Jin, 2007, The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis, J. Gastroenterol., 42, 475, 10.1007/s00535-007-2020-5 Bayraktar, 1996, The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B, J. Viral. Hepat., 3, 129, 10.1111/j.1365-2893.1996.tb00003.x Hayashi, 2011, Animal models for the study of liver fibrosis: new insights from knockout mouse models, Am. J. Physiol. Gastrointest. Liver Physiol., 300, G729, 10.1152/ajpgi.00013.2011 Reddy, 1996, A simplified method for the analysis of hydroxyproline in biological tissues, Clin. Biochem., 29, 225, 10.1016/0009-9120(96)00003-6 Wang, 2012, Immune mechanisms of Concanavalin A model of autoimmune hepatitis, World J. Gastroenterol., 18, 119, 10.3748/wjg.v18.i2.119 Hou, 2009, Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells, World J. Gastroenterol., 15, 4499, 10.3748/wjg.15.4499 Soares, 2011, Purification of a lectin from Canavalia ensiformis using PEG-citrate aqueous two-phase system, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 879, 457, 10.1016/j.jchromb.2010.12.030 Carambia, 2010, CD4 T cells in hepatic immune tolerance, J. Autoimmun., 34, 23, 10.1016/j.jaut.2009.08.006 Kimura, 1999, Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A, Int. Immunol., 11, 1491, 10.1093/intimm/11.9.1491 Louis, 2000, Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis, Hepatology, 31, 381, 10.1002/hep.510310218 Kamiyoshi, 2009, Endogenous alpha-calcitonin gene-related peptide mitigates liver fibrosis in chronic hepatitis induced by repeated administration of concanavalin A, Liver Int., 29, 642, 10.1111/j.1478-3231.2008.01841.x Liang, 2013, Preventive effect of halofuginone on concanavalin A-induced liver fibrosis, PLoS One, 8, e82232, 10.1371/journal.pone.0082232 Mohamed, 2014, Hepatoprotective effects of early pentoxifylline administration on hepatic injury induced by concanavalin A in rat, Can. J. Physiol. Pharmacol., 92, 490, 10.1139/cjpp-2014-0085 Feng, 2009, Stearoyl-CoA desaturase 1 deficiency protects mice from immune-mediated liver injury, Lab. Invest., 89, 222, 10.1038/labinvest.2008.105 Friedman, 2000, Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury, J. Biol. Chem., 275, 2247, 10.1074/jbc.275.4.2247 Liu, 2011, Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib, J. Hepatol., 55, 612, 10.1016/j.jhep.2010.11.035 Ali, 2004, Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair, Cell Biochem. Funct., 22, 67, 10.1002/cbf.1082 Wan, 2014, Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A, Braz. J. Med. Biol. Res., 47, 655, 10.1590/1414-431X20143704 Liang, 2014, The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis, Scand. J. Immunol., 79, 163, 10.1111/sji.12144 Deugnier, 2011, Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years, Gastroenterology, 141, 1202, 10.1053/j.gastro.2011.06.065 Sobbe, 2015, Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox, J. Gastroenterol. Hepatol., 30, 638, 10.1111/jgh.12720 Shi, 2012, Protective effect of andrographolide against concanavalin A-induced liver injury, Naunyn Schmiedebergs Arch. Pharmacol., 385, 69, 10.1007/s00210-011-0685-z Tiegs, 2007, Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury, Z. Gastroenterol., 45, 63, 10.1055/s-2006-927397 Ito, 1996, Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C, Hepatology, 23, 669, 10.1002/hep.510230403 Usui, 2004, Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells, Hematol. J., 5, 505, 10.1038/sj.thj.6200565 Drucker, 2010, Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration, J. Autoimmun., 34, 29, 10.1016/j.jaut.2009.08.003 Malchow, 1812, Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling, Biochim. Biophys. Acta, 2011, 290 Ueyama, 2011, Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin, Antivir. Ther., 16, 1081, 10.3851/IMP1864 Atanasiu, 2007, Hepcidin-central regulator of iron metabolism, Eur. J. Haematol., 78, 1, 10.1111/j.1600-0609.2006.00772.x Lee, 2009, Regulation of hepcidin and iron-overload disease, Annu. Rev. Pathol., 4, 489, 10.1146/annurev.pathol.4.110807.092205 Fujita, 2007, Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C, Mol. Med., 13, 97, 10.2119/2006-00057.Fujita Tsochatzis, 2010, Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C, J. Viral. Hepat., 17, 800, 10.1111/j.1365-2893.2009.01244.x Liu, 2012, Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus, PLoS One, 7, e46631, 10.1371/journal.pone.0046631 Ryan, 2012, Pegylated interferon-alpha induced hypoferremia is associated with the immediate response to treatment in hepatitis C, Hepatology, 56, 492, 10.1002/hep.25666 Gehrke, 2003, Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron, Blood, 102, 371, 10.1182/blood-2002-11-3610 Wang, 2013, Inhibiting heme oxygenase-1 attenuates rat liver fibrosis by removing iron accumulation, World J. Gastroenterol., 19, 2921, 10.3748/wjg.v19.i19.2921